1
|
Bambouskova M, Potuckova L, Paulenda T, Kerndl M, Mogilenko DA, Lizotte K, Swain A, Hayes S, Sheldon RD, Kim H, Kapadnis U, Ellis AE, Isaguirre C, Burdess S, Laha A, Amarasinghe GK, Chubukov V, Roddy TP, Diamond MS, Jones RJ, Simons DM, Artyomov MN. -Itaconate confers tolerance to late NLRP3 inflammasome activation. The Journal of Immunology 2021. [DOI: 10.4049/jimmunol.206.supp.15.11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/09/2023]
Abstract
Abstract
Itaconate is a unique regulatory metabolite that is induced upon toll-like receptor (TLR) stimulation in myeloid cells. Here, we demonstrate major inflammatory tolerance and cell death phenotypes associated with itaconate production in activated macrophages. We show that endogenous itaconate is a key regulator of the signal 2 of NLRP3 inflammasome activation after long LPS priming which establishes tolerance to late NLRP3 inflammasome activation. We show that itaconate acts synergistically with iNOS and the ability of various TLR ligands to establish NLRP3 inflammasome tolerance depends on the pattern of co-expression of IRG1 and iNOS. Mechanistically, itaconate accumulation upon prolonged inflammatory stimulation prevents full caspase-1 activation and processing of gasdermin D, which we demonstrate to be post-translationally modified by endogenous itaconate. Altogether, our data demonstrate that metabolic rewiring in inflammatory macrophages establishes tolerance to NLRP3 inflammasome activation which, if uncontrolled, can result in pyroptotic cell death and tissue damage.
Collapse
|
2
|
Bambouskova M, Potuckova L, Paulenda T, Kerndl M, Mogilenko DA, Lizotte K, Swain A, Hayes S, Sheldon RD, Kim H, Kapadnis U, Ellis AE, Isaguirre C, Burdess S, Laha A, Amarasinghe GK, Chubukov V, Roddy TP, Diamond MS, Jones RG, Simons DM, Artyomov MN. Itaconate confers tolerance to late NLRP3 inflammasome activation. Cell Rep 2021; 34:108756. [PMID: 33691097 PMCID: PMC8039864 DOI: 10.1016/j.celrep.2021.108756] [Citation(s) in RCA: 101] [Impact Index Per Article: 33.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2020] [Revised: 12/09/2020] [Accepted: 01/26/2021] [Indexed: 12/21/2022] Open
Abstract
Itaconate is a unique regulatory metabolite that is induced upon Toll-like receptor (TLR) stimulation in myeloid cells. Here, we demonstrate major inflammatory tolerance and cell death phenotypes associated with itaconate production in activated macrophages. We show that endogenous itaconate is a key regulator of the signal 2 of NLR family pyrin domain containing 3 (NLRP3) inflammasome activation after long lipopolysaccharide (LPS) priming, which establishes tolerance to late NLRP3 inflammasome activation. We show that itaconate acts synergistically with inducible nitric oxide synthase (iNOS) and that the ability of various TLR ligands to establish NLRP3 inflammasome tolerance depends on the pattern of co-expression of IRG1 and iNOS. Mechanistically, itaconate accumulation upon prolonged inflammatory stimulation prevents full caspase-1 activation and processing of gasdermin D, which we demonstrate to be post-translationally modified by endogenous itaconate. Altogether, our data demonstrate that metabolic rewiring in inflammatory macrophages establishes tolerance to NLRP3 inflammasome activation that, if uncontrolled, can result in pyroptotic cell death and tissue damage. Bambouskova et al. determine the in vitro phenotype of Irg1−/− macrophages and define itaconate as a key regulator of tolerance to late NLRP3 inflammasome activation.
Collapse
Affiliation(s)
- Monika Bambouskova
- Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA; Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA
| | - Lucie Potuckova
- Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA
| | - Tomas Paulenda
- Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA
| | - Martina Kerndl
- Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA; Institute for Vascular Biology, Centre for Physiology and Pharmacology, Medical University Vienna, 1090 Vienna, Austria; Christian Doppler Laboratory for Arginine Metabolism in Rheumatoid Arthritis and Multiple Sclerosis, 1090 Vienna, Austria
| | - Denis A Mogilenko
- Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA
| | - Kate Lizotte
- Agios Pharmaceuticals, 88 Sidney Street, Cambridge, MA 02139, USA
| | - Amanda Swain
- Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA
| | - Sebastian Hayes
- Agios Pharmaceuticals, 88 Sidney Street, Cambridge, MA 02139, USA
| | - Ryan D Sheldon
- Van Andel Research Institute, Metabolic and Nutritional Programming, Center for Cancer and Cell Biology, Grand Rapids, MI 49503, USA
| | - Hyeryun Kim
- Agios Pharmaceuticals, 88 Sidney Street, Cambridge, MA 02139, USA
| | - Unnati Kapadnis
- Agios Pharmaceuticals, 88 Sidney Street, Cambridge, MA 02139, USA
| | - Abigail E Ellis
- Van Andel Research Institute, Metabolic and Nutritional Programming, Center for Cancer and Cell Biology, Grand Rapids, MI 49503, USA
| | - Christine Isaguirre
- Van Andel Research Institute, Metabolic and Nutritional Programming, Center for Cancer and Cell Biology, Grand Rapids, MI 49503, USA
| | - Samantha Burdess
- Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA
| | - Anwesha Laha
- Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA
| | - Gaya K Amarasinghe
- Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA
| | - Victor Chubukov
- Agios Pharmaceuticals, 88 Sidney Street, Cambridge, MA 02139, USA
| | - Thomas P Roddy
- Agios Pharmaceuticals, 88 Sidney Street, Cambridge, MA 02139, USA
| | - Michael S Diamond
- Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA; Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO 63110, USA; The Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy Programs, Washington University School of Medicine, St. Louis, MO 63110, USA
| | - Russell G Jones
- Van Andel Research Institute, Metabolic and Nutritional Programming, Center for Cancer and Cell Biology, Grand Rapids, MI 49503, USA
| | - Donald M Simons
- Agios Pharmaceuticals, 88 Sidney Street, Cambridge, MA 02139, USA
| | - Maxim N Artyomov
- Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.
| |
Collapse
|
3
|
Kalev P, Hyer ML, Gross S, Konteatis Z, Chen CC, Fletcher M, Lein M, Aguado-Fraile E, Frank V, Barnett A, Mandley E, Goldford J, Chen Y, Sellers K, Hayes S, Lizotte K, Quang P, Tuncay Y, Clasquin M, Peters R, Weier J, Simone E, Murtie J, Liu W, Nagaraja R, Dang L, Sui Z, Biller SA, Travins J, Marks KM, Marjon K. MAT2A Inhibition Blocks the Growth of MTAP-Deleted Cancer Cells by Reducing PRMT5-Dependent mRNA Splicing and Inducing DNA Damage. Cancer Cell 2021; 39:209-224.e11. [PMID: 33450196 DOI: 10.1016/j.ccell.2020.12.010] [Citation(s) in RCA: 78] [Impact Index Per Article: 26.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/11/2020] [Revised: 10/30/2020] [Accepted: 12/10/2020] [Indexed: 12/13/2022]
Abstract
The methylthioadenosine phosphorylase (MTAP) gene is located adjacent to the cyclin-dependent kinase inhibitor 2A (CDKN2A) tumor-suppressor gene and is co-deleted with CDKN2A in approximately 15% of all cancers. This co-deletion leads to aggressive tumors with poor prognosis that lack effective, molecularly targeted therapies. The metabolic enzyme methionine adenosyltransferase 2α (MAT2A) was identified as a synthetic lethal target in MTAP-deleted cancers. We report the characterization of potent MAT2A inhibitors that substantially reduce levels of S-adenosylmethionine (SAM) and demonstrate antiproliferative activity in MTAP-deleted cancer cells and tumors. Using RNA sequencing and proteomics, we demonstrate that MAT2A inhibition is mechanistically linked to reduced protein arginine methyltransferase 5 (PRMT5) activity and splicing perturbations. We further show that DNA damage and mitotic defects ensue upon MAT2A inhibition in HCT116 MTAP-/- cells, providing a rationale for combining the MAT2A clinical candidate AG-270 with antimitotic taxanes.
Collapse
Affiliation(s)
- Peter Kalev
- Biology, Agios Pharmaceuticals, Inc., Cambridge, MA 02139, USA
| | - Marc L Hyer
- Pharmacology, Agios Pharmaceuticals, Inc., Cambridge, MA 02139, USA
| | - Stefan Gross
- Biochemistry and Biophysics, Agios Pharmaceuticals, Inc., Cambridge, MA 02139, USA
| | - Zenon Konteatis
- Chemistry, Agios Pharmaceuticals, Inc., Cambridge, MA 02139, USA
| | - Chi-Chao Chen
- Bioinformatics, Agios Pharmaceuticals, Inc., Cambridge, MA 02139, USA
| | - Mark Fletcher
- Bioinformatics, Agios Pharmaceuticals, Inc., Cambridge, MA 02139, USA
| | - Max Lein
- Drug Metabolism and Pharmacokinetics, Agios Pharmaceuticals, Inc., Cambridge, MA 02139, USA
| | - Elia Aguado-Fraile
- Clinical Biomarkers, Agios Pharmaceuticals, Inc., Cambridge, MA 02139, USA
| | - Victoria Frank
- Biology, Agios Pharmaceuticals, Inc., Cambridge, MA 02139, USA
| | - Amelia Barnett
- Biology, Agios Pharmaceuticals, Inc., Cambridge, MA 02139, USA
| | - Everton Mandley
- Pharmacology, Agios Pharmaceuticals, Inc., Cambridge, MA 02139, USA
| | - Joshua Goldford
- Cell Metabolism, Agios Pharmaceuticals, Inc., Cambridge, MA 02139, USA
| | - Yue Chen
- Drug Metabolism and Pharmacokinetics, Agios Pharmaceuticals, Inc., Cambridge, MA 02139, USA
| | - Katie Sellers
- Cell Metabolism, Agios Pharmaceuticals, Inc., Cambridge, MA 02139, USA
| | - Sebastian Hayes
- Cell Metabolism, Agios Pharmaceuticals, Inc., Cambridge, MA 02139, USA
| | - Kate Lizotte
- Cell Metabolism, Agios Pharmaceuticals, Inc., Cambridge, MA 02139, USA
| | - Phong Quang
- Biology, Agios Pharmaceuticals, Inc., Cambridge, MA 02139, USA
| | - Yesim Tuncay
- Biology, Agios Pharmaceuticals, Inc., Cambridge, MA 02139, USA
| | - Michelle Clasquin
- Cell Metabolism, Agios Pharmaceuticals, Inc., Cambridge, MA 02139, USA
| | - Rachel Peters
- Toxicology, Agios Pharmaceuticals, Inc., Cambridge, MA 02139, USA
| | - Jaclyn Weier
- Biology, Agios Pharmaceuticals, Inc., Cambridge, MA 02139, USA
| | - Eric Simone
- Chemistry, Manufacturing and Control, Agios Pharmaceuticals, Inc., Cambridge, MA 02139, USA
| | - Joshua Murtie
- Biology, Agios Pharmaceuticals, Inc., Cambridge, MA 02139, USA; Pharmacology, Agios Pharmaceuticals, Inc., Cambridge, MA 02139, USA
| | - Wei Liu
- Bioinformatics, Agios Pharmaceuticals, Inc., Cambridge, MA 02139, USA
| | - Raj Nagaraja
- Drug Metabolism and Pharmacokinetics, Agios Pharmaceuticals, Inc., Cambridge, MA 02139, USA
| | - Lenny Dang
- Biochemistry and Biophysics, Agios Pharmaceuticals, Inc., Cambridge, MA 02139, USA
| | - Zhihua Sui
- Chemistry, Agios Pharmaceuticals, Inc., Cambridge, MA 02139, USA
| | - Scott A Biller
- Chemistry, Agios Pharmaceuticals, Inc., Cambridge, MA 02139, USA
| | - Jeremy Travins
- Chemistry, Agios Pharmaceuticals, Inc., Cambridge, MA 02139, USA
| | - Kevin M Marks
- Biology, Agios Pharmaceuticals, Inc., Cambridge, MA 02139, USA
| | - Katya Marjon
- Biology, Agios Pharmaceuticals, Inc., Cambridge, MA 02139, USA.
| |
Collapse
|